GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shield Therapeutics PLC (LSE:STX) » Definitions » EV-to-FCF

Shield Therapeutics (LSE:STX) EV-to-FCF : -0.11 (As of May. 01, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Shield Therapeutics EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Shield Therapeutics's Enterprise Value is £2.74 Mil. Shield Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2023 was £-24.83 Mil. Therefore, Shield Therapeutics's EV-to-FCF for today is -0.11.

The historical rank and industry rank for Shield Therapeutics's EV-to-FCF or its related term are showing as below:

LSE:STX' s EV-to-FCF Range Over the Past 10 Years
Min: -67.34   Med: -10.3   Max: 0.03
Current: -0.11

During the past 9 years, the highest EV-to-FCF of Shield Therapeutics was 0.03. The lowest was -67.34. And the median was -10.30.

LSE:STX's EV-to-FCF is ranked worse than
100% of 511 companies
in the Drug Manufacturers industry
Industry Median: 22.28 vs LSE:STX: -0.11

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-01), Shield Therapeutics's stock price is £0.0135. Shield Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was £-0.120. Therefore, Shield Therapeutics's PE Ratio for today is At Loss.


Shield Therapeutics EV-to-FCF Historical Data

The historical data trend for Shield Therapeutics's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shield Therapeutics EV-to-FCF Chart

Shield Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only -8.10 -37.73 -50.44 -4.14 -1.12

Shield Therapeutics Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -4.14 - -1.12 -

Competitive Comparison of Shield Therapeutics's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Shield Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shield Therapeutics's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shield Therapeutics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Shield Therapeutics's EV-to-FCF falls into.



Shield Therapeutics EV-to-FCF Calculation

Shield Therapeutics's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=2.736/-24.829
=-0.11

Shield Therapeutics's current Enterprise Value is £2.74 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Shield Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2023 was £-24.83 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shield Therapeutics  (LSE:STX) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Shield Therapeutics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.0135/-0.120
=At Loss

Shield Therapeutics's share price for today is £0.0135.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Shield Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was £-0.120.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Shield Therapeutics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Shield Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Shield Therapeutics (LSE:STX) Business Description

Traded in Other Exchanges
Address
Northern Design Centre, Baltic Business Quarter, Gateshead Quays, Newcastle, GBR, NE8 3DF
Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals which address areas of high unmet medical need. The company's operating segments are based on key products including Accrufer/Feraccru, used as a novel oral treatment for iron deficiency anemia in patients, which is commercially available, and PT20 used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from Feraccru segment.